Immunotherapy of distant metastatic disease by Schadendorf, D. (D.) et al.
Annals of Oncology 20 (Supplement 6): vi41–vi50, 2009
doi:10.1093/annonc/mdp253
Immunotherapy of distant metastatic disease
D. Schadendorf1*, S. M. Algarra2, L. Bastholt3, G. Cinat4, B. Dreno5, A. M. M. Eggermont6,
E. Espinosa7, J. Guo8, A. Hauschild9, T. Petrella10, J. Schachter11 & P. Hersey12
1Department of Dermatology, University Hospital Essen, Essen, Germany; 2Department of Oncology, Clinica Universitaria de Navarra, Pamplona, Spain; 3Department
of Oncology, Odense University Hospital, Odense, Denmark; 4Department of Oncology, Instituto de Oncologia Angel Roffo, Buenos Aires, Argentina; 5Clinique of
Dermatologie, Hoˆtel Dieu, Nantes Cedex 01, France; 6Department of Surgical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center,
Rotterdam, The Netherlands; 7Department of Oncology, Hospital La Paz, Madrid, Spain; 8Department of Oncology, Peking University School of Oncology, Beijing,
China; 9Department of Dermatology, University of Kiel, Kiel, Germany; 10Toronto Sunnybrook Regional Cancer Center, Toronto, Canada; 11The Ella Institute for
Treatment and Research of Melanoma, Tel Hashomer, Israel and 12Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, New South Wales, Australia
Immunotherapy of metastatic melanoma consists of various approaches leading to specific or non-specific
immunomodulation. The use of FDA-approved interleukin (IL)-2 alone, in combination with interferon a, and/or with various
chemotherapeutic agents (biochemotherapy) is associated with significant toxicity and poor efficacy that does not
improve overall survival of 96% of patients. Many studies with allogeneic and autologous vaccines have demonstrated no
clinical benefit, and some randomised trials even showed a detrimental effect in the vaccine arm. The ongoing effort to
develop melanoma vaccines based on dendritic cells and peptides is driven by advances in understanding antigen
presentation and processing, and by new techniques of vaccine preparation, stabilisation and delivery. Several agents that
have shown promising activity in metastatic melanoma including IL-21 and monoclonal antibodies targeting cytotoxic T
lymphocyte-associated antigen 4 (anti-CTLA-4) or CD137 are discussed. Recent advances of intratumour gene transfer
technologies and adoptive immunotherapy, which represents a promising although technically challenging direction,
are also discussed.
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Depending on tumour thickness, mitotic index, presence of
ulceration, lymphocyte infiltration, age, gender and anatomical
site, 20–25% of all primary melanoma will spread.
Dissemination to distant visceral organs is, with the exception of
rare cases of surgery for oligometastatic disease, almost
invariably a sign of incurable, stage IV disease that has a median
survival time of6–12 months and a 3-year survival rate of only
10–15% [1]. This is mainly because no treatments of distant
metastatic melanoma have demonstrated over the last three
decades any survival benefit. Innovative systemic treatment
approaches including immunotherapy have focused on
metastatic melanoma and are being tested with an increasing
intensity. The term ‘immunotherapy’ is used for non-specific as
well as specific immunomodulation that encompasses a number
of different approaches summarised below.
cytokines
interleukin-2 and interferon a
Interleukin (IL)-2 and interferon (IFN) a are the most widely
used immunomodulating drugs in metastatic melanoma.
Analysis of eight clinical trials of high-dose IL-2 in 270 patients
conducted between 1985 and 1993 [2] reported an overall
objective response rate of 16% and a complete response in 6%
of patients; importantly, 4% of patients remained
progression-free, which indicates that, in some patients, IL-2
therapy can achieve durable complete remission of the disease.
IL-2 (Proleukin) was approved for distant metastatic disease
based on a series of phase II studies by the FDA in 1998 in the
USA, but not by the EMEA in Europe. Treatment with IL-2
is associated with significant toxicity that includes severe
hypotension and vascular leak syndrome, resulting in
interstitial and pulmonary oedema, renal and hepatic
dysfunction, cardiovascular failure, neurological disturbances,
nausea, vomiting and thrombocytopenia [3]. This has limited
its use to selected patients with good organ function who are
treated by experienced clinicians at selected specialised centres.
Several studies have identified pre-treatment factors
predicting response to IL-2 therapy [4, 5]. Univariate analyses
revealed that the ECOG performance status, number of
involved organs, site of metastases and serum lactate
dehydrogenase (LDH) were all predictive of survival in stage IV
melanoma. The pre-treatment peripheral neutrophil count was
identified as an independent prognostic factor [6]; the data
were validated on blood samples from patients in the EORTC
18951 biochemotherapy trial [7]. These results indicated that
selection of patients in stage IV melanoma studies is highly
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critical; selection of patients for high-dose IL-2 therapy based
on performance status, serum LDH and peripheral neutrophil
counts seems to be of importance. However, prospective
randomised clinical trials are needed to demonstrate whether
the patient selection itself or its combination with high-dose
IL-2 leads to the observed significant clinical benefit in a subset
of patients.
The most effective IL-2 therapy appears to be the original
high-dose bolus regimen used by the National Cancer Institute
(NCI) [2]. Both long-term, low-dose administration and
different subcutaneous schedules have all failed to produce
acceptable new regimens with reduced toxicity and higher
efficacy compared with that of high-dose IL-2 therapy alone.
The continuous infusion schedule has been used in most of the
randomised biochemotherapy trials published. A recent report
showed a response rate of 19.2% in patients receiving high-dose
bolus IL-2 who progressed on biochemotherapy [8]. Overall,
despite the limited number of patients who benefit from IL-
2-based immunotherapy, its curative potential makes it an
essential component of immunological strategies in the
treatment of metastatic malignant melanoma [9].
IFNa is only rarely used as a single agent in stage IV
melanoma, but has achieved objective response rates of 10–15
% independent of the dose and schedule [10]. Pegylated (PEG)
IFNa, an improved IFNa formulation with increased
bioavailability [11], was recently used in a trial of stage IV
metastatic melanoma patients as a single agent and showed
dose-dependent response rates in the range 6–12% [12]. In
recent phase II trials, a combination of PEG-IFNa2a with
dacarbazine (DTIC) [13] and PEG-IFNa2b with temozolomide
[14] increased response rates to 24% and 18%, respectively.
Combining IFNa and IL-2 did not demonstrate significantly
better response rates and survival than those with either agent
alone [15, 16].
Biochemotherapy, a combination of IL-2 and/or IFNa with
chemotherapeutic agents such as DTIC, temozolomide,
fotemustine, cisplatin, carboplatin, vinblastine, paclitaxel or
docetaxel, has also not demonstrated a better survival than that
with the agents alone and has been associated with increased
toxicity (Table 1) [17, 18]. In summary, biochemotherapy
improves response rates but not OS and cannot be
recommended for treatment of metastatic malignant
melanoma.
interleukins 15 and 21
The common cytokine receptor c-chain is a critical component
of the receptors for IL-2, 4, 7, 9, 15 and 21. IL-21 and IL-15
have sequence homology with IL-2.
IL-21 is produced by activated CD4+ T cells and NK-cells.
IL-21 has pronounced effects on B cell differentiation and
antibody production, mostly via CD40. Furthermore,
activation of the IL-21 receptor leads to multiple effects on T
cells, including proliferation, differentiation and activation of
cytokine and chemokine production. IL-21 has effects on both
CD8+ T cells and CD4+ T cells, and synergises with IL-15 in
inducing an optimal and sustained antigen-specific CD8+ T cell
Table 1. Randomised trials with IFN- and/or IL-2-containing regimens
Year (author) Regimen No. patients Median survival (months) Signif. Ref.
1991 (Falkson) D 6 IFN 64 9.6 versus 17.6 P < 0.01 [19]
1993 (Thomson) D 6 IFN 170 7.6 versus 8.8 NS [20]
1994 (Bajetta) D 6 IFNa 242 11 versus 11 versus 13 NS [21]
1998 (Falkson) D versus D/IFN versus
D/T versus D/IFN/T
258 10 versus 9 versus 8 versus 9.5 NS [22]
2000 (Middleton) D/IFN versus DCBT 105 6.5 versus 6.5 NS [23]
2001 (Young) D 6 IFN 61 7.2 versus 4.8 NS [24]
2005 (Kaufmann) TMZ 6 IFN 282 8.4 versus 9.7 NS [25]
2005 (Vuoristo) D/nIFN versus DCBT/rIFN
versus D/rIFN versus DCBT/rIFN
108 11 versus 10 versus 9 versus 7.5 NS [26]
1993 (Sparano) IL-2 6 IFN 85 10.2 versus 9.7 NS [15]
2002 (Agarwala) IL-2 6 histamine 305 9.1 versus 8.2 NS [27]
1997 (Keilholz) IL-2/IFN 6 C 133 9 versus 9 NS [28]
1998 (Johnston) CDBT 6 IFN/IL-2 65 5.5 versus 5.0 NS [29]
1999 (Dorval) C/IL-2 6 IFN 117 10.4 versus 10.9 NS [30]
1999 (Rosenberg) CDT 6 IFN/IL-2 102 15.8 versus 10.7 P < 0.06 [31]
2001 (Hauschild) D/IFN 6 IL-2 290 11 versus 11 NS [32]
2002 (Eton) CVD 6 IFN/IL-2 183 9.2 versus 11.9 P < 0.06 [33]
2002 (Atzpodien) D/B/C/T 6 IFN/IL-2 124 13 versus 12 NS [34]
2002 (Ridolfi) CVD 6 IFN/IL-2 176 9.5 versus 11.0 NS [35]
2005 (Keilholz) CD/IFN 6 IL-2 363 9 versus 9 NS [36]
2006 (Bajetta) CVD 6 IFN/IL-2 139 12 versus 11 NS [37]
2008 (Atkins) CVD 6 IFN/IL-2 416 8.7 versus 8.4 NS [38]
aDose 3 or 9 MIU.
D, dacarbazine; C, cisplatin; V, vinblastine; B, BCNU (carmustine); T, tamoxifen; IFN, interferon a; IL-2, interleukin-2; TMZ, temozolomide; NS, not
significant; n, natural; r, recombinant.
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response [39]. In contrast to IL-2, IL-21 does not enhance the
proliferation of T regulatory cells. IL-21 may therefore promote
autoimmunity and consequently also antitumour immunity in
cancer patients.
IL-15 was initially identified based on its ability to stimulate
proliferation of IL-2-dependent T cell lines in the presence of
neutralising anti-IL-2 antibodies. IL-15 mediates functions very
similarly to IL-2, as these two cytokines share receptor
b-subunits. However, distinctly different a-subunits lead to
differences in in vivo immune function [40].
IL-21 is being investigated in clinical phase I/II studies as
a single drug in patients with metastatic melanoma, and recent
reports indicate that the treatment is biologically active and
well tolerated [41, 42].
monoclonal antibodies
anti-cytotoxic T lymphocyte-associated antigen 4
Activation or ‘priming’ of naı¨ve T cells requires recognition of
the antigen by the T cell receptor (TCR) and provision of co-
stimulatory signals. The engagement of the molecule B7 on the
antigen-presenting cell with its ligand CD28 on the T cell
launches a signalling cascade that is required for full T cell
activation [43]. Following antigen stimulation of the T cell,
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
receptors are up-regulated and move to the cell surface. These
receptors have greater affinity for B7 than CD28, and their
binding induces an inhibitory signal that down-regulates T cell
activation in response to a stimulus. CTLA-4 serves as a natural
breaking mechanism that returns T cells to homeostasis
following an immune response; it controls the duration and
intensity of the immune response.
Monoclonal antibodies that bind to CTLA-4 can block the
interaction between B7 and CTLA-4. Inhibition of this negative
switch may break peripheral tolerance to self-tissues and induce
antitumour responses [44]. Two fully human IgG monoclonal
antibodies recognising CTLA-4, ipilimumab (MDX-010) and
tremelimumab (CP-675,206), have been tested, alone or in
combination, in numerous phase II trials and in four phase III
trials. Comprehensive reviews were recently published on
targeting the CTLA-4 receptor as a strategy for melanoma
treatment [45, 46], and on clinical development of ipilimumab
[47] and tremelimumab [48].
ipilimumab
Activity of ipilimumab in patients with metastatic melanoma
was examined alone, in combination with chemotherapy or
vaccines and in various dose regimens.
In a randomised phase II trial, 72 chemotherapy-naı¨ve
patients were treated with ipilimumab (3 mg/kg every 4 weeks
for 4 months) alone or in combination with DTIC. The median
OS for the monotherapy and combination groups was 351
[95% CI, 208–596] and 386 [95% CI, 253–571] days,
respectively, and 10% of patients were alive after 2 to >4 years
of follow-up in both therapy arms, indicating that the
treatment can achieve long-term control of the disease [49].
To assess the activity of ipilimumab in combination with
a vaccine, 56 patients were randomised in a phase II study of 3
mg/kg every 3 weeks or a 3 mg/kg initial dose of ipilimumab
followed by 1 mg/kg every 3 weeks, with both cohorts receiving
concomitant vaccination with two modified HLA-A*0201-
restricted peptides [50]. Overall response rate was 13%; better
clinical responses were observed in patients with grade 3/4
autoimmune toxicity. This result was later confirmed by
a subsequent analysis of additional data, which reported that
some of the immune-related adverse events were observed in
62% of 139 overall treated patients and were associated with
a greater probability of objective antitumour response
(P = 0.0004) [51]. The most common grade 3/4 immune-
related adverse events were colitis/diarrhoea and dermatitis,
which responded to systemic steroids without significantly
affecting the efficacy of ipilimumab therapy [52]. These studies
indicate that induction of manageable autoimmunity in
patients with metastatic melanoma treated with ipilimumab
could be a surrogate marker of objective and durable clinical
response.
Although earlier studies used ipilimumab at doses of 3 mg/kg
every 3–4 weeks, results from more recent dose-escalation trials
showed an increase in overall response and long-term survival
benefits with increasing dose, and suggested 10 mg/kg every
3 weeks for 4 months (Q3Wx4) as an optimal treatment [53].
This induction regimen along with a maintenance treatment of
10 mg/kg ipilimumab every 12 weeks starting at week 24
(Q12W) has been used in most ongoing phase II and phase III
clinical trials.
The Q3Wx4 regimen of ipilimumab with Q12W
maintenance showed clinical activity in the form of either
objective response or stable disease in 27% of 155 patients with
metastatic melanoma who developed progressive disease on
a median number of two prior therapies [54]. Immune-related
grade 3/4 adverse events occurred in 21.9% of patients. The
study reported median OS of 10.2 months and 1-year survival
of 46.7% (95% CI, 38.6–55.6). Four patterns of response were
observed: (a) response in baseline lesions; (b) stable disease
with slow, steady decline in total tumour burden; (c) response
after initial increase in total tumour burden; (d) response in
index and new lesions after the appearance of new lesions [54].
It is of note that 7 of 26 patients who developed new lesions
after 12 weeks of treatment experienced shrinking and
stabilisation of the new lesions during additional follow-up.
This result demonstrated that development of new lesions in
patients receiving ipilimumab might not always indicate
progressive disease and treatment failure as defined by modified
World Health Organization (mWHO) criteria [55]. Novel,
immune-related response criteria (irRC) that may more
accurately describe response to immunotherapy and avoid
premature treatment cessation in patients with disease
progression before response were presented at ASCO 2008.
Contrary to mWHO criteria, irRC (a) only consider measurable
lesions (>1 cm), (b) define total tumour burden as the sum of
index lesions identified at baseline and new lesions detected
after baseline and (c) aim for follow-up after progressive disease
to detect late activity [56].
Overall positive results of ipilimumab in patients with
metastatic melanoma led to the initiation of a pivotal trial in
first-line treatment comparing DTIC with or without
ipilimumab. Another phase III trial of ipilimumab alone or in
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combination with a peptide vaccine as second-line therapy is
also ongoing.
tremelimumab
Early-phase clinical studies of tremelimumab demonstrated
acceptable toxicity (diarrhoea/colitis, dermatitis, fatigue,
pancreatitis, Grave’s disease) and similar efficacy of 10 mg/kg
monthly and 15 mg/kg quarterly doses of the antibody [57]
with median survival of 10.3 and 11 months, respectively [58].
Survival outcomes were better than the historical median
survival of 7 months and independent of the patients’ objective
response [58].
Activity of tremelimumab as a single agent (15 mg/kg
quarterly, ‡1 dose, 44% of patients ‡2 doses) in 246 previously
treated patients with metastatic melanoma was assessed in
a single-arm phase II study. Although the objective response
rate was only 8.3%, the duration of the response (183+ to 540+
days) and the median OS of 10.1 months indicate a role for
tremelimumab in this patient population [59].
The quarterly dose regimen (15 mg/kg) was chosen for
a phase III clinical trial since it was associated with a lower
incidence of serious adverse events and comparable efficacy
[57]. That trial, a randomised study investigating
tremelimumab as a single agent in comparison with a standard
chemotherapy (DTIC or temozolomide) in previously
untreated 324 and 319 patients, respectively, was stopped based
on a second interim analysis for futility in March 2008. Median
OS by intent-to-treat was 11.8 months in the tremelimumab
arm, and 10.7 months in the chemotherapy arm, with a hazard
ratio (HR) (chemotherapy over tremelimumab) of 1.04 (95%
CI, 0.84, 1.28). The study concluded that the antibody failed to
demonstrate an improvement in OS as a first-line treatment in
patients with metastatic melanoma when compared with
standard chemotherapy [60]. Data from subsequent phase II
and phase III studies will be useful to further evaluate the
dosing regimen and the relationship between tumour response
and survival.
A combination of tremelimumab (15 mg/kg quarterly)
administered concurrently with high-dose IFNa2b was assessed
in a phase II trial of 16 previously treated patients with
metastatic melanoma and showed acceptable toxicity and an
overall response rate of 19% [61].
Collectively, development of therapies based on selective
inhibition of the CTLA-4 receptor with monoclonal antibodies
is a promising direction in treatment of stage IV melanoma, but
the recently reported lack of efficacy of tremelimumab as
a single agent in first-line treatment indicates that future
investigative efforts of anti-CTLA-4 agents may focus on
combination studies and patients with refractory tumours.
Also, the unique kinetics of response to ipilimumab therapy
will likely lead to revision of the criteria that describe response
to CTLA-4 antibodies.
anti-CD137 (4-1BB)
Inducible receptor-like protein 4-1BB is expressed by both
CD4+ and CD8+ T cells after activation. Cross-linking of 4-
1BB, either by 4-1BB ligand binding or antibody ligation,
delivers a co-stimulatory signal to enhance T cell activation and
proliferation. Pre-clinical studies demonstrated that the
administration of 4-1BB (CD137) monoclonal antibodies can
induce antitumour immune responses. In a pre-clinical B-16
mouse melanoma model, a combination of granulocyte
monocyte colony-stimulating factor (GM-CSF)-secreting
tumour cell immunotherapy and anti-4-1BB monoclonal
antibody treatment resulted in rejection of established tumours
[62]. In a pre-clinical B16F10 mouse melanoma model,
a combination treatment with anti-CD4+ and anti 4-1BB
monoclonal antibodies potentiated the observed anti-cancer
effects [63]. A phase I dose-escalation study of BMS-663513, an
agonist anti-CD137 human monoclonal antibody, in 54
metastatic melanoma patients reported manageable toxicity
(up to 15 mg/kg), with fatigue, transaminitis and neutropenia
being the most common adverse events, and clinical activity
that justifies its further development both as a single agent and
in combination [64]. A large, randomised phase II clinical
study with BMS-663513 in previously treated melanoma
patients with stage IV disease is currently ongoing.
anti-integrin
Human monoclonal antibody targeting av integrin, CNTO 95,
was found to inhibit growth of human melanoma tumours in
nude mice (10 mg/kg, 3 times a week) by 80% and in nude
rats by >99% [65]. Based on these preclinical data, a dose-
escalating phase I clinical trial assessed the safety and
pharmacokinetics of CNTO 95 in 24 patients with advanced
refractory solid tumours. The antibody was well tolerated up
to weekly doses of 10 mg/kg, and had a dose-dependent half-life
ranging from 0.19 to 11.81 days over the doses 0.1–10 mg/kg,
indicating tissue binding at low doses [66]. An ongoing phase I/
II trial is investigating the safety and efficacy of CNTO 95 alone
or in combination with DTIC in 138 patients with metastatic
melanoma.
Volociximab (M200) is a chimeric monoclonal antibody that
specifically recognises a5b1 integrin and inhibits tumour
angiogenesis by interrupting the binding of endothelial cells to
fibronectin in extracellular matrix. A pilot, single-arm phase II
study of 40 patients with metastatic melanoma tested
a combination of volociximab (10 mg/kg i.v. bi-weekly) with
DTIC (1000 mg/m2 monthly) and reported stable disease in
53% of patients at 8 weeks with median time to progression 72
days. The combination therapy was relatively well tolerated,
with reported adverse events including nausea, constipation,
vomiting, hypertension and thrombosis [67]. A recent phase II
study of volociximab (15 mg/kg weekly for 8 weeks) as a single
agent in 19 patients who failed at least one prior therapy
reported poor clinical activity at 8 weeks (overall response rate
of 5%) but indicated a potential correlation between the
expression of a5b1 integrin in tumours or stroma and clinical
response [68].
Etaracizumab (Abegrin), formerly known as Vitaxin or
MEDI-522, is a humanised monoclonal antibody that
specifically targets the integrin avb3 overexpressed on various
tumour cells, angiogenic blood vessels and osteoclasts, and
results in antitumour, antiangiogenic and antiosteolytic
activities [69]. Results from a phase II study in 112 patients
with distant metastatic melanoma examined antitumour
activity and safety of etaracizumab (8 mg/kg/week) with or
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without DTIC (1000 mg/m2 once every 3 weeks). The therapy
with or without DTIC reported median progression-free
survival of 2.6 or 1.4 months, respectively, and was generally
well tolerated with adverse events including neutropenia,
thrombocytopenia, anaemia and leukopenia. Approximately
70% of patients were alive at 6 months in each arm [70]. Later
evaluation of the trial data showed a 12.7-month median
survival for patients treated with etaracizumab alone and
a 9.4-month median survival for patients treated with
etaracizumab plus DTIC, indicating that the antibody may
prolong survival in melanoma patients. However, a 24-month
follow-up was less positive and resulted in withdrawal of the
agent from further development in metastatic melanoma at the
end of 2006.
vaccines
The rationale for developing a melanoma therapeutic vaccine is
based on several observations: (a) the ability of melanoma to
initiate an immune response that can induce spontaneous
regression; (b) the effectiveness of vaccines for treating
melanoma in animal models; (c) the association of the presence
of lymphocytic tumour infiltration with prognosis in
melanoma patients; (d) the identification of numerous human
melanoma-associated antigens; (e) relatively low toxicity and
few side-effects of vaccines in humans with melanoma.
Rosenberg and co-workers [71] stated that despite great
progress in the field of tumour immunology over the past
decade, optimism regarding the clinical application of currently
available cancer vaccine approaches is based more on surrogate
end points than on clinical tumour regression. In the NCI
surgery branch cancer vaccine trials involving 440 metastatic
cancer patients (96% melanoma), the objective response rate
was very low (2.6%) and was comparable to the response rate of
4.0% obtained by others in 40 studies including 756 patients
[71]. These disappointing results in patients with distant
metastatic melanoma are often softened by arguments that such
immunosuppressed patients are unsuitable for vaccine
development studies and that vaccines will likely be successful
only in immune-competent patients after full resection of their
tumour(s) (adjuvant setting). However, it is precisely in this
setting (large adjuvant trials in resected stage II–IV melanoma)
where results with vaccines have not been positive or even
indicated that the vaccines are potentially detrimental.
allogeneic and autologous vaccines
The vaccination of tumour patients with autologous and
allogeneic cell-based vaccines has a long tradition [72]. The
largest two studies to date, which assessed the efficacy of an
allogeneic cancer vaccine from three cell lines (Canvaxin) in
patients with stage III or IV melanoma, were closed
prematurely based on the advice of the Independent Data
Monitoring Committee (IDMC) [73]. In these trials, >1400
patients were randomised to Canvaxin + bacillus Calmette–
Guerin (BCG) or placebo + BCG after resectional surgery.
There was a survival disadvantage with Canvaxin treatment in
both studies. The median survival in the stage III study had not
been reached, but the 5-year survival rate was 59% for the
Canvaxin patients and 68% for the placebo patients. In the
stage IV study, the median survival was 32 months for the
Canvaxin patients and 39 months for the placebo patients, with
a 5-year survival of 40% and 45%, respectively.
In contrast to allogeneic vaccines, autologous vaccines are
prepared from tumours of individual patients. Vitespen
(Oncophage, formerly HSPPC-96) is a tumour-derived, HSP–
peptide complex vaccine based on the pioneering work of
Pramod K. Srivastava [74]. It was earlier examined in a trial
with 64 stage IV melanoma patients [75] and showed no
toxicity of the treatment and increased T cell activity associated
with the vaccine application.
The most recent, phase III trial comparing Vitespen with
a physician choice therapy (2:1 randomisation) in 322 stage
IV cutaneous melanoma patients not previously treated for
metastatic disease found similar overall survival (OS) in both
arms (P = 0.32; HR = 1.16; 95% CI, 0.69–1.71) based on
intention-to-treat analysis of survival for all patients [76]. Non-
significant difference was also found for OS of patients
stratified by substage (M1a, M1b, M1c). However, exploratory
landmark analysis of survival of patients who received >10
vaccines showed, after adjustment for survival bias, a separation
of both arms in Kaplan–Meier plots in favour of the Vitespen-
treated patients for all patients and statistical significance for
combined data from M1a + M1b patients (P = 0.03;
HR = 0.45; 95% CI, 0.21–0.96). The study also reported
a correlation between the number of immunisations and
improved survival in favour of the vaccine in all patients, as
well as in M1a and M1b, but not M1c, substages [76]. Whether
these results will be convincing enough for further clinical
development is still open.
MAGE-3
A number of clinical trials involving antigens encoded by genes
of the MAGE family, particularly MAGE-3, have been
documented and demonstrated tumour regression in
melanoma patients [77]. These tumour regressions appeared to
be mediated by low-level cytolytic T lymphocyte (CTL)
responses. A recombinant MAGE-A3 fusion protein—Prot.D
MAGE-A3/His—was engineered as a fusion protein with
a lipidated protein D derived from Haemophilus influenzae. A
recent, proof-of-concept, randomised, open study with the
MAGE-A3 protein combined with different immunological
adjuvants—AS02B or AS15—assessed the adjuvants for toxicity
and clinical and immunological responses. The MAGE-A3
protein was administered as first-line treatment to 68 patients
with unresectable stage III or stage IV M1a melanoma; in
combination with AS15 it yielded higher anti-MAGE-3
antibody titre, stronger T cell induction and long-lasting
clinical response [78]. A randomised trial in patients with
resected stage IIIB and IIIC melanoma is planned to commence
in late 2008.
peptide-based vaccines
The identification of tumour-specific antigens recognised by
autologous cytolytic CD8+ T cells has led to the use of defined
antigens in therapeutic vaccination of cancer patients.
Although overall response rates to all peptide-based vaccines
have been disappointing in distant metastatic melanoma
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patients [71], a new interest is stimulated by insights into
tissue-specific processing of the immunogenic epitopes of
proteins and by the discovery of unusually long cytotoxic
T lymphocyte epitopes that may lead to identification of
new targets and an improvement in peptide immunogenicity
[79]. Longer peptides harbouring particular peptide epitopes
allow adequate epitope processing and consequently better
peptide vaccine efficacy [80]; also, they can be synthesised
with known post-translational modifications and/or protease-
resistant peptide bonds to regulate their processing
independently of tissue-specific proteolysis, and to stabilise
them in vivo [79].
dendritic-cell-based vaccines
Dendritic cells (DCs) play a crucial role in the induction of
antigen-specific T cell responses and are considered to be
promising adjuvants for use in active immunotherapy of
metastatic malignancies. The generation of immune responses
against tumour antigens following DC immunisation has been
demonstrated, and favourable clinical responses have been
reported in some patients [81]. However, the data on the
usefulness of DCs for melanoma immunotherapy remain
inconclusive because of varying DC preparation and
vaccination protocols, the use of different antigens and a lack
of rigorous criteria for defining clinical responses. Issues
regarding the optimal dose and clinical setting for the
application of DC vaccines remain to be resolved.
In one of the earliest studies [82], DCs pulsed with MAGE-
3A1 tumour peptide and a recall antigen (tetanus toxoid or
tuberculin) were injected into 11 advanced stage IV melanoma
patients. A significant expansion of MAGE-3A1-specific CD8+
cytotoxic T lymphocyte precursors were induced in eight of
those patients, and regressions of individual skin metastases
were observed in six patients. Regressing skin metastases in two
of the patients demonstrated erythema and CD8+ T cell
infiltration, whereas non-regressing lesions lacked CD8+ T cells
as well as MAGE-3 mRNA expression.
In a randomised phase III trial conducted by Schadendorf
et al. [83], patients received autologous peptide-loaded DC
vaccination or DTIC (850 mg/m2) at 4-week intervals. DC
vaccines loaded with MHC class I and II-restricted peptides
were applied subcutaneously at 2-week intervals for the first five
vaccinations and every 4 weeks thereafter. At the time of the
first interim analysis, 55 and 53 patients had been enrolled into
the DTIC- and DC-arm, respectively. Since the overall response
was low (DTIC: 5.5%, DC: 3.8%) and not significantly different
in the two arms, the study was closed. Many factors could
have affected the efficacy of the vaccine. These include the low
and variable maturation status of DCs, administration of lower
than the expected number of DCs per class I peptide,
subcutaneous instead of intradermal route of administration
and a lack of non-specific helper proteins like KLH or tetanus
toxoid. Although various small clinical phase I/II studies were
conducted using DCs, no results of other randomised trials
in melanoma have been published [84]. Current technologies
try to benefit from improved understanding of DC biology and
use mostly transfection techniques of RNA from the whole
tumour or RNA of specific tumour antigens.
In summary, vaccine development in melanoma has gone
through a difficult phase and, to date, no vaccination procedure
has shown statistically significant efficacy in the adjuvant or
metastatic setting [85]. Currently available data do not justify
the use of vaccination for the treatment of patients with
cutaneous melanoma outside of a clinical trial.
intratumoural gene transfer therapy
The first clinical trial of gene therapy for cancer was performed
in the early 1990s in patients with melanoma, and several
intratumoural gene-therapy-based protocols have been
attempted since then. Conclusive evidence demonstrating the
clinical efficacy and therapeutic response using this approach
for melanoma is yet to be established.
A phase I/II study [86] was recently conducted to evaluate
the safety, efficacy and biological effects of intratumoural
injections of adenovirus–IL-2 (TG1024) in patients with
advanced solid tumours including melanoma. Twenty-five
patients with metastatic melanoma were treated with
intratumoural TG1024 injections in combination with DTIC.
Objective responses were observed in five metastatic melanoma
patients, of whom two demonstrated complete responses [86].
Intratumoural injections of a plasmid harbouring the IL-12
gene in nine stage IV melanoma patients [87] resulted in
clinical benefit in three patients, and eight patients exhibited
transient responses. Successful results were also observed when
intratumoural injections of a similar plasmid were used to treat
lesions in 12 metastatic melanoma patients in a phase I/IB trial
[88]. The size of the treated lesions decreased by >30% in 5 of
the 12 patients. No responses were seen in untreated lesions.
Results from a recent phase II study with intratumour
injections (up to 18 cycles) of OncoVEXGM-CSF—an oncolytic
herpes simplex virus vector encoding GM-CSF—into 43 stage
IIIc and IV patients who failed previous therapies reported an
encouraging 28% objective response and very minor side-
effects [89]. Injected tumours routinely responded, often with
local complete response, within 2 months of therapy. More
importantly, systemic long-term responses were observed. The
responses were observed late and were independent of the
disease stage: six complete responses, six partial responses and
seven stable diseases were reported. A phase III trial in 360
previously treated, unresectable melanoma patients is planned
and will be initiated at the beginning of 2009.
These results show that intratumoural injections of
a cytokine gene can produce beneficial clinical effects and that
intratumoural gene therapy may be a promising therapy for
patients with metastatic melanoma.
adoptive immunotherapy
Adoptive cell transfer (ACT) immunotherapy is based on ex
vivo activation and expansion of tumour reactive lymphocytes
taken from the tumour-bearing host and their re-infusion back
into the patient [90].
The availability of the T cell growth factor in the form of
recombinant IL-2 in the 1980s promoted the investigation and
use of cell therapy in human cancer with lymphokine activated
killer (LAK) cells and IL-2, demonstrating non-specific
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antitumour activity [91]. On the other hand, tumour-
infiltrating lymphocytes (TILs) are T cells that have specific
antitumour activity, and in melanoma these cells can be reliably
generated [92].
Eighty-six patients with metastatic melanoma were treated
with TILs and high-dose (HD) IL-2 in the early 1990s. The
overall response rate was 34%, and responses were also
documented in patients failing prior HD IL-2 therapy [93]. In
2002 Dudley et al. [94] reported that ACT of highly selected
tumour-reactive T cells into 13 HLA-A2+ refractory metastatic
melanoma patients after a non-myeloablative conditioning
regimen approach resulted in the persistent clonal repopulation
of T cells in these cancer patients, proliferation of transferred
cells in vivo, functional activity of T cells and trafficking to
tumour sites. Six of the 13 patients had objective clinical
responses to treatment, and four patients demonstrated mixed
responses. This study established the proof of principle that
normally expressed ‘self-antigens’ can be useful targets for
human tumour immunotherapy if the autoimmune
consequences of such treatment are not of major concern.
Mackensen et al. [95] generated Melan-A-specific CTLs by ex
vivo stimulation of purified CD8+ peripheral blood
lymphocytes with mature Melan-A pulsed DCs and reported
that 3 of 11 patients experienced objective clinical responses
after infusion of the T cells with a 6-day course of low-dose IL-
2. Regression of melanoma lesions was observed in
subcutaneous and lymphatic, but not in visceral metastases.
Powell et al. [96] treated nine patients with distant metastatic
melanoma who were vaccinated with GP-100:209–217 peptide.
The patients received autologous peripheral blood
mononuclear cells stimulated ex vivo with the peptide and were
pretreated with non-myeloablative chemotherapy; the cells
were given concomitantly with high-dose IL-2. Two patients
experienced some evidence of melanocyte-directed
autoimmunity [96].
A recent report [97] demonstrated a durable clinical
remission of a patient with refractory metastatic melanoma
who was treated with autologous CD4 T cell clones specific for
melanoma-associated antigen NY-ESO-1, isolated and
expanded ex vivo; the treatment also led to endogenous
responses against melanoma antigens other than NY-ESO-1
[97].
Studies carried out at the surgery branch of NCI
demonstrated that, in addition to IL-2, lymphodepletion with
chemotherapy was crucial to support the transferred cells.
Lymphodepletion was believed to eliminate T regulatory
(suppressor) cells and to reduce competition for homeostatic
cytokines (IL-7, IL-15) vital for T cell survival. Bulk TIL
populations that were rapidly expanded in vitro were preferred
over cloned TIL populations [98]. The protocol used a non-
myeloablative but lymphodepleting regimen consisting of i.v.
administration of cyclophosphamide (60 mg/kg/day for 2 days)
followed by fludarabine (25 mg/m2/day for 5 days). This was
followed by the administration of bulk TILs and HD IL-2. A
response rate of 51% was achieved in the first 35 metastatic
melanoma patients, with three patients achieving a durable
complete response ongoing for >3 years after therapy. Further
improvement in the clinical efficacy of the TIL programme was
achieved by adding total body irradiation with up to 1200 cGy
in three divided doses. The patients treated with this
programme received peripheral stem cell support, and the
response rate reached 70% [99].
Conversion of normal peripheral blood lymphocytes (PBLs)
into antitumour cells by transduction with genes encoding one
of the TCRs relevant to tumour cells is under study [100]. This
approach is being explored for the immunotherapy of patients
with melanoma and common epithelial cancers. Thirty-one
patients with metastatic melanoma were treated by autologous
PBLs transduced by MART-1-specific TCRs following non-
myeloablative conditioning. Four patients had objective
tumour regression [99].
Studies to optimise ACT include examination of the role of
cytokines such as IL-7, IL-15 and others, and the addition of
other immunomodulatory agents such as anti-CTLA-4. One of
the most important steps toward developing a technically more
simple way of producing effective TILs is by using ‘young’,
unselected TILs. This technology uses the entire tumour to
rapidly expand TILs for administration without testing for
antitumour reactivity. This simple method may facilitate the
adoption of ACT by more cancer centres and provide this
effective therapy to more patients [101].
conclusion
The poor efficacy and high toxicity of current
immunotherapeutic approaches used to treat distant metastatic
melanoma underscore an urgent need for novel therapies that
take advantage of recent advances in understanding the biology
of the disease. In parallel, introducing novel criteria for the
selection of potential therapy responders would result in a more
targeted use of current therapies and spare future non-
responders from unnecessary toxicity.
Early clinical trials with monoclonal antibodies targeting
CTLA-4, CD137 or integrins show generally manageable
toxicity, and results from large randomised studies are needed
to assess the future role of these agents in metastatic melanoma.
Combinations with cytotoxic agents appears to be the likely
direction, mainly in patients with refractory tumours.
Development of a vaccine that would show significant clinical
benefit in melanoma has not been successful, but the extent of
research activity in the field and a number of novel approaches
indicate that such an approach remains attractive.
Intratumoural gene transfer represents a promising direction of
yet uncertain clinical benefit. Adoptive therapy has
demonstrated a remarkable response rate and efficacy in
a number of small studies, but it is a complex and labour-
intensive technology that would require extensive optimisation
before its introduction into mainstream clinical practice.
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